London, UK – 9th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on ...

Healthcare providers receive data from many disparate sources: hospitals, doctors’ offices, labs and lab machines, medical devices, pharmacies, and more. Investment in the correct infrastructure to ...

MILWAUKEE, WI, November 19, 2024 (EZ Newswire) -- As biopharmaceutical sponsors face increasing challenges in securing investigative sites for their clinical trials, the ability to reduce ...

BOSTON & PLEASANTON, Calif.--(BUSINESS WIRE)--One of the largest, most in-depth surveys of clinical data management professionals shows that the time it takes companies to design and release clinical ...

In today's fast-paced and ever-evolving landscape of clinical trials, the ability to efficiently analyze and visualize data has become paramount. The vast amounts of data generated from these trials ...

A recent influx of digital technology has unlocked tremendous potential for clinical trials. For an industry that has traditionally relied on patients’ paper intake forms and manual data entry into ...

Clinical data archiving, the movement of inactive patient information from a production electronic health record (EHR) to a long-term storage solution, has been happening at major hospitals and health ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily ...

It is now a commonplace to propose high-dimensional molecular characterization within the translational research objectives of contemporary clinical trials. Similarly, most of these methods are being ...

- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo ...

Shares of biotechnology firm Curis gained ground in today's trading session, buoyed by an encouraging clinical data update. While market analysts have reaffi ...